$150 Million

OdonateTherapeutics

Initial Public Offering

Bookrunner, December 2017

Odonate is a clinical-stage biopharmaceutical Company focused on developing therapeutics that improve and extend the lives of patients with cancer. The Company’s sole asset is tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.